Harbour BioMed Announces Phase II Clinical Data Presentation of HBM4003 and Tislelizumab Combo for MSS Metastatic Colorectal Cancer at ESMO 2025

Reuters

2025/07/30

Harbour BioMed Announces Phase II Clinical Data Presentation of HBM4003 and Tislelizumab Combo for MSS Metastatic Colorectal Cancer at ESMO 2025

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company specializing in novel antibody therapeutics for immunology and oncology, has announced that it will present Phase II clinical data on its anti-CTLA-4 antibody, porustobart (HBM4003), in combination with tislelizumab for microsatellite stable $(MSS)$ metastatic colorectal cancer (mCRC). The presentation will take place at the ESMO Congress 2025 in Berlin, Germany, from October 17-21, 2025. The study, conducted at multiple centers, involved heavily pretreated non-liver metastatic MSS mCRC patients. Preliminary efficacy and safety data will be featured in a poster session. Porustobart, developed using the HCAb Harbour Mice® platform, offers unique properties such as significant Treg cell depletion and optimized pharmacokinetics. The company has observed positive efficacy and safety data in monotherapy and combination trials for various solid tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN38456) on July 30, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2555610067"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555610067\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555610067?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-30 08:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555610067","market":"fut","top_or_hot":-1,"title":"Harbour BioMed Announces Phase II Clinical Data Presentation of HBM4003 and Tislelizumab Combo for MSS Metastatic Colorectal Cancer at ESMO 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Harbour BioMed Announces Phase II Clinical Data Presentation of HBM4003 and Tislelizumab Combo for MSS Metastatic Colorectal Cancer at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harbour BioMed (HKEX: 02142), a global biopharmaceutical company specializing in novel antibody therapeutics for immunology and oncology, has announced that it will present Phase II clinical data on its anti-CTLA-4 antibody, porustobart (HBM4003), in combination with tislelizumab for microsatellite stable <a href=\"https://laohu8.com/S/MSS\">$(MSS)$</a> metastatic colorectal cancer (mCRC). The presentation will take place at the ESMO Congress 2025 in Berlin, Germany, from October 17-21, 2025. The study, conducted at multiple centers, involved heavily pretreated non-liver metastatic MSS mCRC patients. Preliminary efficacy and safety data will be featured in a poster session. Porustobart, developed using the HCAb Harbour Mice® platform, offers unique properties such as significant Treg cell depletion and optimized pharmacokinetics. The company has observed positive efficacy and safety data in monotherapy and combination trials for various solid tumors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN38456) on July 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harbour BioMed Announces Phase II Clinical Data Presentation of HBM4003 and Tislelizumab Combo for MSS Metastatic Colorectal Cancer at ESMO 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarbour BioMed Announces Phase II Clinical Data Presentation of HBM4003 and Tislelizumab Combo for MSS Metastatic Colorectal Cancer at ESMO 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-30 08:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Harbour BioMed Announces Phase II Clinical Data Presentation of HBM4003 and Tislelizumab Combo for MSS Metastatic Colorectal Cancer at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harbour BioMed (HKEX: 02142), a global biopharmaceutical company specializing in novel antibody therapeutics for immunology and oncology, has announced that it will present Phase II clinical data on its anti-CTLA-4 antibody, porustobart (HBM4003), in combination with tislelizumab for microsatellite stable <a href=\"https://laohu8.com/S/MSS\">$(MSS)$</a> metastatic colorectal cancer (mCRC). The presentation will take place at the ESMO Congress 2025 in Berlin, Germany, from October 17-21, 2025. The study, conducted at multiple centers, involved heavily pretreated non-liver metastatic MSS mCRC patients. Preliminary efficacy and safety data will be featured in a poster session. Porustobart, developed using the HCAb Harbour Mice® platform, offers unique properties such as significant Treg cell depletion and optimized pharmacokinetics. The company has observed positive efficacy and safety data in monotherapy and combination trials for various solid tumors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN38456) on July 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL5dHmkZ:1","article_id":"2555610067","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555610067","pubTimestamp":1753833730,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Harbour BioMed Announces Phase II Clinical Data Presentation of HBM4003 and Tislelizumab Combo for MSS Metastatic Colorectal Cancer at ESMO 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire  on July 30, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1161":"生物科技","02142":"和铂医药-B","BK1574":"生物医药B类股"},"translate_title":"Harbour BioMed宣布在ESMO 2025上展示HBM4003和替雷利珠单抗组合治疗MSS转移性结直肠癌的II期临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":0.9},"content_text":"Harbour BioMed Announces Phase II Clinical Data Presentation of HBM4003 and Tislelizumab Combo for MSS Metastatic Colorectal Cancer at ESMO 2025\n    \n\n        Harbour BioMed (HKEX: 02142), a global biopharmaceutical company specializing in novel antibody therapeutics for immunology and oncology, has announced that it will present Phase II clinical data on its anti-CTLA-4 antibody, porustobart (HBM4003), in combination with tislelizumab for microsatellite stable $(MSS)$ metastatic colorectal cancer (mCRC). The presentation will take place at the ESMO Congress 2025 in Berlin, Germany, from October 17-21, 2025. The study, conducted at multiple centers, involved heavily pretreated non-liver metastatic MSS mCRC patients. Preliminary efficacy and safety data will be featured in a poster session. Porustobart, developed using the HCAb Harbour Mice® platform, offers unique properties such as significant Treg cell depletion and optimized pharmacokinetics. The company has observed positive efficacy and safety data in monotherapy and combination trials for various solid tumors.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN38456) on July 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}